[{"address1": "1325 Boylston Street", "address2": "Suite 401", "city": "Boston", "state": "MA", "zip": "02215", "country": "United States", "phone": "857 321 8020", "website": "https://www.rapportrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Steven M. Paul M.D.", "age": 73, "title": "Founder & Independent Chairman", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 568987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Abraham N. Ceesay M.B.A.", "age": 46, "title": "CEO, President, Treasurer & Director", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 902035, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Troy A. Ignelzi", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 459683, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cheryl  Gault", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 281110, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Bredt M.D., Ph.D.", "age": 59, "title": "Founder & Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karina  Chmielewski", "title": "Chief Information Officer & Head of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julie  DiCarlo", "title": "Head of Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen A. Wilkinson", "age": 52, "title": "Chief People Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Swamy  Yeleswaram Ph.D.", "age": 61, "title": "Chief Development Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arnold R. Gammaitoni Pharm.D.", "age": 57, "title": "Senior Vice President of Medical Affairs", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.75, "open": 16.67, "dayLow": 15.685, "dayHigh": 17.27, "regularMarketPreviousClose": 16.75, "regularMarketOpen": 16.67, "regularMarketDayLow": 15.685, "regularMarketDayHigh": 17.27, "forwardPE": -4.3712735, "volume": 112235, "regularMarketVolume": 112235, "averageVolume": 112923, "averageVolume10days": 95940, "averageDailyVolume10Day": 95940, "bid": 15.87, "ask": 16.47, "bidSize": 100, "askSize": 100, "marketCap": 589978944, "fiftyTwoWeekLow": 12.095, "fiftyTwoWeekHigh": 29.74, "fiftyDayAverage": 17.719, "twoHundredDayAverage": 21.0, "currency": "USD", "enterpriseValue": 270968256, "floatShares": 14943677, "sharesOutstanding": 36576500, "sharesShort": 1499086, "sharesShortPriorMonth": 1808388, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.040999997, "heldPercentInsiders": 0.06537, "heldPercentInstitutions": 1.01192, "shortRatio": 12.33, "shortPercentOfFloat": 0.0446, "impliedSharesOutstanding": 37982400, "bookValue": 8.834, "priceToBook": 1.8259, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -71846000, "trailingEps": -1.96, "forwardEps": -3.29, "enterpriseToEbitda": -3.677, "52WeekChange": -0.22451925, "SandP52WeekChange": 0.19995654, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RAPP", "underlyingSymbol": "RAPP", "shortName": "Rapport Therapeutics, Inc.", "longName": "Rapport Therapeutics, Inc.", "firstTradeDateEpochUtc": 1717767000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d4728dbb-210b-3528-bef2-c2644f3a08ab", "messageBoardId": "finmb_1828746377", "gmtOffSetMilliseconds": -18000000, "currentPrice": 16.13, "targetHighPrice": 42.0, "targetLowPrice": 35.0, "targetMeanPrice": 37.33333, "targetMedianPrice": 35.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 320660992, "totalCashPerShare": 8.767, "ebitda": -73696000, "totalDebt": 1651000, "quickRatio": 45.17, "currentRatio": 45.913, "debtToEquity": 0.511, "operatingCashflow": -60739000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]